LSA
DNLI icon

Leonteq Securities AG’s Denali Therapeutics DNLI Stock Holding History

Leonteq Securities AG’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50
Closed -$1.39K – 1235
2022
Q4 		$1.39K Sell
50
-40
-44% -$1.19K ﹤0.01% 1209
2022
Q3 		$2.76K Sell
90
-13
-13% -$423 ﹤0.01% 1170
2022
Q2 		$3.03K Sell
103
-34
-25% -$891 ﹤0.01% 1179
2022
Q1 		$4.41K Buy
137
+39
+40% +$1.34K ﹤0.01% 1173
2021
Q4 		$4.37K Buy
98
+33
+51% +$1.56K ﹤0.01% 1192
2021
Q3 		$3.28K Buy
+65
New +$3.66K ﹤0.01% 1084

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Leonteq Securities AG's DNLI Position: Q1 2023 in Review

Leonteq Securities AG sold out of Denali Therapeutics (DNLI) in Q1 2023, closing a stake of 50 shares — an estimated $1.39K sold.

Leonteq Securities AG first reported a position in DNLI in Q3 2021 and held it in 6 quarters. The position peaked at $4.41K in Q1 2022. 202 funds tracked by Wall St. Rank hold DNLI as of Q1 2023.

  • Leonteq Securities AG reported no remaining Denali Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Leonteq Securities AG sold 50 Denali Therapeutics shares in Q1 2023, an estimated $1.39K.
  • Leonteq Securities AG first reported a position in Denali Therapeutics in Q3 2021 and held it in 6 quarters.
  • Leonteq Securities AG's Denali Therapeutics position peaked at $4.41K in Q1 2022.
  • 202 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2023.

Based on Leonteq Securities AG's 13F filing for Q1 2023, filed 11 Mar 2026.